Skip to main content

IL-23

      RT @RichardPAConway: Rahman et al. 2 year results on dactylitis/enthesitis from Discover-2 study guselkumab. Sustained i
      2 years 5 months ago
      Rahman et al. 2 year results on dactylitis/enthesitis from Discover-2 study guselkumab. Sustained improvements seen over time @RheumNow #EULAR2022 POS1028 https://t.co/VZhw6g4kCB
      RT @RichardPAConway: 2 year guselkumab data from Discover-2 @DrLauraCoates et al. Continue incremental improvements acro
      2 years 5 months ago
      2 year guselkumab data from Discover-2 @DrLauraCoates et al. Continue incremental improvements across all key domains through 2 years of treatment @RheumNow #EULAR2022 POS1017 https://t.co/wcSKCID9Yt
      At EULAR 2022, I look forward to key topics and presentations in psoriatic arthritis (PsA). I will be sharing the details of these studies once they are presented. There are new therapies that…
      RT @drdavidliew: Have always been fascinated by the idea that some b/tsDMARDs might have effects on pain and fatigue bey
      2 years 5 months ago
      Have always been fascinated by the idea that some b/tsDMARDs might have effects on pain and fatigue beyond inflammation control. Baricitinib data in RA before, & now this from guselkumab. Substantial effect on pain beyond SJC/CRP attributable? POS1030 #EULAR2022 #IL23 @RheumNow https://t.co/fxqIGnlkwU
      RT @Janetbirdope: Proton Rahman discusses #PsA and #fatigue ⬇️ in #Guselkumab RCTs. 2/3 of fatigue was explained by
      2 years 5 months ago
      Proton Rahman discusses #PsA and #fatigue ⬇️ in #Guselkumab RCTs. 2/3 of fatigue was explained by pt factors - pt global and pain, skin, joints, CRP, function drove the data. Ask pt and treat what is treatable. #OP0025 @eular @RheumNow https://t.co/x4T6sPEi8o
      RT @drdavidliew: in case you're interesting in the causal diagram for the mediation modelling for this:

      far from proven
      2 years 5 months ago
      in case you're interesting in the causal diagram for the mediation modelling for this: far from proven, but certainly does raise some questions about a potential advantage of IL-23 inhibitors in a crowded PsA market #EULAR2022 @RheumNow https://t.co/bSuE3tDHUO
      RT @drdavidliew: Minimal disease activity achivement by PsA domain over 2y, in guselkumab phase 3

      Everyone goes on abou
      2 years 5 months ago
      Minimal disease activity achivement by PsA domain over 2y, in guselkumab phase 3 Everyone goes on about skin efficacy with guselkumab, but pretty good early on for enthesitis & swollen joints too... has challenged my uninformed thinking! POS1067 #EULAR2022 #IL23 @RheumNow https://t.co/chCWeFd05o
      RT @doctorRBC: How do we treat fatigue in our PsA patients? Guselkumab PsA trials showed systemic disease activity/func
      2 years 5 months ago
      How do we treat fatigue in our PsA patients? Guselkumab PsA trials showed systemic disease activity/function, joint manifestations, and skin involvement accounted for 62% of variability in fatigue. How do we account for the other 38%? @RheumNow #EULAR2022 ABST#OP0025
      RT @RichardPAConway: Rahman et al. Factors associated with fatigue and its improvement in trials IL23i guselkumab. Disea
      2 years 5 months ago
      Rahman et al. Factors associated with fatigue and its improvement in trials IL23i guselkumab. Disease activity/function (34%), joints (16%), skin (12%) but 38.5% of fatigue variability remains unexplained. @RheumNow #EULAR2022 OP0025 https://t.co/C08R0IWM3S https://t.co/QnCvPwEwKS